Page last updated: 2024-08-26

alpha-glutamyltryptophan and AIDS-Related Opportunistic Infections

alpha-glutamyltryptophan has been researched along with AIDS-Related Opportunistic Infections in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aboulafia, D; Dezube, BJ; Gill, P; Lee, J; Noy, A; Scadden, DT; Tulpule, A; Walmsley, S	1
Cabriales, S; Espina, BM; Gill, PS; Howard, W; Scadden, DT; Shea, K; Tulpule, A	1

Trials

2 trial(s) available for alpha-glutamyltryptophan and AIDS-Related Opportunistic Infections

Article	Year
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Adult; Aged; AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Anti-HIV Agents; CD4 Lymphocyte Count; Dipeptides; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Placebos; Remission Induction; Sarcoma, Kaposi; Self Administration; Viral Load	2005
Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4 Topics: Administration, Intranasal; Adult; AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; CD4 Lymphocyte Count; Dipeptides; Disease Progression; Drug Administration Schedule; Endothelial Growth Factors; Fatigue; Female; Headache; HIV Protease Inhibitors; Humans; Lymphokines; Male; Middle Aged; Nausea; Paresthesia; Protein Isoforms; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2000

Article

Year

Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5

Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Adult; Aged; AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Anti-HIV Agents; CD4 Lymphocyte Count; Dipeptides; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Placebos; Remission Induction; Sarcoma, Kaposi; Self Administration; Viral Load

2005

Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

Topics: Administration, Intranasal; Adult; AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; CD4 Lymphocyte Count; Dipeptides; Disease Progression; Drug Administration Schedule; Endothelial Growth Factors; Fatigue; Female; Headache; HIV Protease Inhibitors; Humans; Lymphokines; Male; Middle Aged; Nausea; Paresthesia; Protein Isoforms; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2000